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Abstract
Background: Chronic kidney disease (CKD) is characterized by the progressive accumulation of various potential toxic
solutes. Furthermore, uremic plasma is a complex mixture hampering accurate determination of uremic toxin levels and the
identification of novel uremic solutes.
Methods: In this study, we applied 1H-nuclear magnetic resonance (NMR) spectroscopy, following three distinct
deproteinization strategies, to determine differences in the plasma metabolic status of stage 3–4 CKD patients and healthy
controls. Moreover, the human renal proximal tubule cell line (ciPTEC) was used to study the influence of newly indentified
uremic solutes on renal phenotype and functionality.
Results: Protein removal via ultrafiltration and acetonitrile precipitation are complementary techniques and both are
required to obtain a clear metabolome profile. This new approach, revealed that a total of 14 metabolites were elevated in
uremic plasma. In addition to confirming the retention of several previously identified uremic toxins, including p-cresyl
sulphate, two novel uremic retentions solutes were detected, namely dimethyl sulphone (DMSO2) and 2-hydroxyisobutyric
acid (2-HIBA). Our results show that these metabolites accumulate in non-dialysis CKD patients from 967 mM (control) to
51629 mM and from 7 (0–9) mM (control) to 32615 mM, respectively. Furthermore, exposure of ciPTEC to clinically relevant
concentrations of both solutes resulted in an increased protein expression of the mesenchymal marker vimentin with more
than 10% (p,0.05). Moreover, the loss of epithelial characteristics significantly correlated with a loss of glucuronidation
activity (Pearson r =20.63; p,0.05). In addition, both solutes did not affect cell viability nor mitochondrial activity.
Conclusions: This study demonstrates the importance of sample preparation techniques in the identification of uremic
retention solutes using 1H-NMR spectroscopy, and provide insight into the negative impact of DMSO2 and 2-HIBA on
ciPTEC, which could aid in understanding the progressive nature of renal disease.
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Introduction
The kidneys play an important role in maintaining total body
homeostasis by facilitating the urinary secretion of both endoge-
nous and exogenous waste products. Chronic kidney disease
(CKD) affects approximately 10% of the adult population in
developed countries. In half of these patients the diagnosis of CKD
is based on the presence of a reduced kidney function (chronic
renal failure; CRF). In CKD patients adequate renal clearance is
compromised resulting in the accumulation of a plethora of uremic
solutes [1]. Nowadays, over 140 uremic toxins have been reported,
divided into three distinct classes based on their physico-chemical
properties. It is well documented that uremic toxins accumulate in
dialysis patients and several biomarkers of CKD have been
identified [2–5]; yet, less is known about the retention of possible
toxic solutes in other patients with a compromised kidney function.
Herget-Rosenthal et al., reported that several uremic toxins are
retained during acute kidney injury including b2-microglobulin,
hippuric acid and 3-carboxyl-4-methyl-5-propyl-2-furanpropionic
acid [6]. Furthermore, our group previously demonstrated that
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plasma levels of hippuric acid, indole-3-acetic acid, indoxyl
sulphate and kynurenic acid are elevated in non-dialysis CRF
patients compared with healthy controls [2].
Although the retention of uremic toxins in dialysis patients is
widely studied, there is a large variation in blood levels reported
for uremic toxins. These discrepancies can be due to differences in
the study population with respect to diet, colonic microbial
metabolism and endogenous metabolism [7,8]. Moreover, precise
determination of uremic toxin concentrations is cumbersome and
dependent on the physico-chemical characteristics of these solutes,
such as protein-binding, which can result in insufficient extraction
of compounds from body fluids, leading to an underestimation of
the true values [9,10]. In addition, plasma is a complex mixture of
proteins, molecules and ions that together can undergo a myriad of
molecular interactions [11]. During 1H-nuclear magnetic reso-
nance (NMR) spectroscopy, the abundance of proteins in complete
plasma results in broad overlapping signals that obscure
resonances of low-molecular-weight metabolites and quantification
of these compounds is hampered due to T2-relaxation processes
[11]. Therefore, deproteinization is required when studying small
organic molecules in plasma, and it is required to optimize
analytical techniques and/or sample preparation methods to
obtain a reliable overview of uremic toxin levels in CKD patients.
In metabolomics studies, generally two analytical approaches
are used: mass spectrometry-based methods and NMR [12].
Recently, Shah et al., reported the plasma metabolite profiles of
stage 2–4 CKD patients using gas and liquid chromatography
coupled to mass spectrometry [13]. Therefore, we investigated
whether NMR could be used as a complementary tool to elucidate
novel biomarkers in kidney disease. The metabolic status of stage
3–4 CKD patients was determined using one-dimensional 1H-
NMR spectroscopy following three previously described depro-
teinization strategies [11], namely ultrafiltration, protein precip-
itation via perchloric acid or via acetonitrile extraction.
Materials and Methods
Ethics Statement
The ethical committee of the Radboud University Nijmegen
Medical Centre on research involving human subjects approved
this study, and written informed consent was obtained from each
patient and each healthy volunteer.
Chemicals
All chemicals were obtained from Sigma (Zwijndrecht, the
Netherlands) unless stated otherwise. Stock solutions of uremic
toxins were prepared in milli-Q and stored at 220uC. The
reference standard of p-cresyl sulphate, kindly provided by Prof.
R. Vanholder (University Hospital Ghent, Belgium), was synthe-
sized as a potassium salt as described previously [14].
Patients and Sample Preparation
Blood samples were obtained from ten patients with CKD stage
3–4 (eGFR: 14–36 ml/min/1.73 m2) during regular check-up and
four adult controls. Clinical characteristics of study subjects are
listed in Table 1. None of the subjects had been fasting at the time
of blood sampling. Blood was collected in an Heparin Vacutainer
and was immediately centrifuged at 3,0006 g for 10 min.
Subsequently, plasma was collected and stored at 220uC. Before
analysis, each patient sample was deproteinized via three distinct
methods: (1) ultrafiltration; plasma samples were deproteinized
using a 10 kD filter (Sartorius). Before use, the filter was washed
twice by centrifugation of water to remove glycerol. (2) perchloric
acid (PCA) extraction; 100 ml of 20% (v/v) PCA was added to
500 ml plasma, samples were then vortexed and placed on ice for
5 min. Next, samples were centrifuged at 12,0006 g for 3 min
and the clear supernatant was used for spectroscopy. (3)
acetonitrile extraction; 1.5 ml of acetonitrile was added to
0.5 ml plasma, mixed thoroughly, followed by centrifugation
(3,0006g for 5 min). Subsequently, the supernatant was dried by
heating at 40uC under N2 flow and finally resuspended in 700 ml
milli-Q. The control samples were deproteinized via ultrafiltration
or acetonitrile extraction. Following protein removal via the
different methods, 20 ml of 20.2 mM trimethylsilyl-2,2,3,3-tetra-
deuteropropionic acid (TSP, sodium salt) in 2H2O was added to
the sample, providing a chemical shift reference (d=0.00), a
concentration reference and a deuterium lock signal. The pH of
the ultrafiltrate was adjusted to 2.5060.05 with concentrated
hydrogen chloride. Finally, 650 ml of the sample was placed in a
5 mm NMR tube (Wilmad Royal Imperial).
One-dimensional 1H-NMR Spectroscopy
Plasma was measured at 500 MHz on a Bruker DRX 500
spectrometer equipped with a triple-resonance inverse (TXI) 1H
[15N, 13C] probe head and equipped with x,y,z gradient coils. 1H
spectra were acquired as 256 transients in 32K data points with a
spectral width of 6002 Hz. Sample temperature was 298 K and
the H2O resonance was pre-saturated by single-frequency
irradiation during a relaxation delay of 10 s, and a 90u excitation
was used. Automated tuning and matching (ATMA) and
shimming (Topshim) was performed on all plasma samples. The
resonances from the metabolites in Table 2 and the TSP singlet
(nine equivalent protons) were fitted semi-automatically with
Lorentzian line shapes. The concentration of the metabolites was
calculated from the relative integrals of the fitted lineshapes using
the known concentration of TSP.
Cell Culture
The human conditionally immortalized proximal tubule
epithelial cell (ciPTEC) line was generated as previously described
by Wilmer et al. [15]. The cells were cultured in phenol red free
DMEM/F12 medium (Gibco/Invitrogen, Breda, the Netherlands)
containing 10% (v/v) fetal calf serum (MP Biomedicals, Uden, the
Netherlands), insulin (5 mg/ml), transferrin (5 mg/ml), selenium
(5 ng/ml), hydrocortisone (36 ng/ml), epithelial growth factor
(10 ng/ml), and tri-iodothyronine (40 pg/ml) at 33uC in a 5% (v/
Table 1. Characteristics of study subjects.
Patients Controlsa
Number 10 4
Age (years) 55612 40612
Women (%) 33 50
Urea (mmol/l) 2069 ND
Creatinine (mmol/l) 227656 20–90
Albumin (g/l) 3764 ND
eGFR (ml/min/1.73 m2)b 2667 ND
Values are shown as mean 6 SD. ND, not determined.
aControl metabolite levels were similar as compared to an established database
(n = 50) from the Radboud University Nijmegen.
beGFR was calculated using the Modification of Diet in Renal Disease (MDRD)
equation (www.nkdep.nih.gov).
doi:10.1371/journal.pone.0071199.t001
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v) CO2 atmosphere. Propagation of cells was maintained by
subculturing the cells at a dilution of 1:3 to 1:6 at 33uC. For
experiments, cells were cultured at 33uC to 40% confluency,
followed by maturation for 7 days at 37uC. Experiments were
performed on the cells between passages 30 and 40, during which
proximal tubule characteristics, such as albumin uptake and
phosphate reabsorption, were maintained [15].
Flow Cytometry
In this study, flow cytometry was used to study both cell viability
and the expression of vimentin, a mesenchymal cell marker.
ciPTEC were seeded at 40% confluence in 12-well plates and
allowed to adhere over night at 33uC followed by maturation for
7 days at 37uC, before being treated for 48 h with clinically
relevant uremic toxin concentrations. In addition, ciPTEC were
also exposed for 48 h to 1 mM 1-methylhistidine, 3-methylhisti-
dine (both as negative control) or indoxyl sulphate as a positive
control. After incubation, cells were harvested using trypsin-
EDTA and centrifuged at 6006 g during 5 min. Subsequently,
supernatant was removed and the cell pellet was resuspended in
100 mL PBS containing 1 mL mouse-a-human Vimentin-PE
(Abcam, Cambridge, UK) followed by 30 min incubation at RT.
Samples were acquired with a BD FACSCalibur (Becton
Dickinson, Breda, the Netherlands) using channel FL-2. Analysis
was performed using Flow Jo software (TreeStar, Ashland, USA),
gating on live cells.
High-performance Liquid Chromatography (HPLC)
HPLC was used to measure UDP-glucuronosyltransferase
(UGT) activity via the glucuronidation of 7-hydroxycoumarin (7-
OCH), as described previously [16,17]. Following exposure to
uremic toxins at clinically relevant concentrations for 48 h,
ciPTEC were incubated with 10 mM 7-OCH for 3 h at 37uC.
Before chromatography, an aliquot of culture medium was
collected and centrifuged at 12,0006 g for 3 min and 50 ml of
the supernatant was injected into the HPLC-system (Spectra-
Physics Analytical, Spectrasystem SCM400). To measure 7-OCH
and 7-OCH glucuronide (7-OCHG) the HPLC was equipped with
a C18 HPLC column (GraceSmart RP 18 5u 150 x 4.6 mm;
Grace, Breda, the Netherlands). Separation was performed at a
flow rate of 1 ml/min with eluent A (95% (v/v) H2O, 5% (v/v)
methanol and 0.2% (v/v) acetic acid) and eluent B (50% (v/v)
H2O, 49% (v/v) acetonitrile and 1% (v/v) tetrahydrofuran) under
the following gradient conditions: 0–3 min, 80–50% eluent A; 3–
8 min, 50% eluent A; 8–9 min, 50–80% eluent A; 9–14 min, 80%
eluent A. The compounds were detected at a wavelength of 316/
382 nm. Standards of the compounds were also run in order to
quantify the amount of metabolites found in the samples. Acquired
data were processed with PC1000 software (Spectrasystem).
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide (MTT) Assay
Mitochondrial succinate dehydrogenase activity was assessed
using the MTT assay. ciPTEC were cultured in a 96 well culture
plate and exposed to DMSO2 or 2-HIBA for 48 h. Next, medium
was removed and 40 ml preheated (37uC) MTT-solution (5 mg 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide/ml
ciPTEC medium) was added and incubated for 4 h at 37uC.
Afterwards, MTT-solution was removed, followed by the addition
of 150 ml DMSO to dissolve produced formazan crystals. The
extinction of the solution was measured at 570 nm using a
Benchmark Plus Microplate Spectrophotometer (Bio-rad).
Statistics
Statistics were performed using GraphPad Prism 5.02 via one-
way analysis of variance (ANOVA) followed by Dunnett’s Multiple
Comparison Test. Differences between groups were considered to
be statistically significant when p,0.05. The software was also
used to perform linear regression analysis and correlation analysis
(Spearman and Pearson). Raw data files are available upon
request.
Table 2. 1H resonance assignments and plasma concentrations of uremic solutes in stage 3–4 CKD patients.
Metabolite Peak no.a Cu (mM) Cmaxb (mM) Control (mM) Literaturec (mM)
1-Methylhistidine 3 34626 87 ,5 468
3-Methylhistidine 4 38625 89 ND 2.7 (0–6)
Hippuric acid 1346111 357 ND 3 (0–5)
p-Cresyl sulphate 2896132 552 ND 1569
Creatinine 1,2 5906276 1143 20–90 72 (57–93)
Dimethyl sulphone 7 51629 108 ,30 967
2-Hydroxyisobutyric acid 9 32615 61 ND 7 (0–9)
N,N-Dimethylglycine 8 23611 46 ,5 2.6 (1.8–3.7)
trigonelline 28624 76 ND ND
Pseudouridine 48615 79 ND 3.261
Betaine 83634 150 ,50 34.6 (24–42)
myo-Inositol 5 4996170 838 ND 30 (21–49)
Dimethylamine 17d NA ND 3.361.5
Trimethylamine N-oxide 6 88642 172 ND 38620
Values are shown as mean (Cu) 6 SD or range (mM) and maximal uremic concentration (Cmax,). ND, not detected; NA, not applicable.
aNumbers correspond to peaks in Fig. 3.
bHypothetical Cmax calculated as Cmax = Cu +2 SD, as previously described [2,3].
cData obtained from the Human Metabolome Database (www.hmdb.ca) [42].
dOnly detected in one patient.
doi:10.1371/journal.pone.0071199.t002
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Results
Influence of Deproteinization on 1H-NMR Spectra
Fig. 1 shows the deproteinized 1H-NMR plasma spectrum
following ultrafiltration (Figure 1A), acetonitrile precipitation
(Figure 1B) and PCA extraction (Figure 1C). Citric acid is clearly
detected following ultrafiltration with a symmetrical quadruplet,
generally referred to as an AB-system, at 2.94 ppm; whereas,
resonance signals are low in the spectral region d 7.00–8.00
(Figure 1A). In contrast, high-resonance signals were observed in
this part of the 1H-NMR spectrum after acetonitrile treatment
(Figure 1B). Hippuric acid showed a triplet at both 7.54 ppm and
7.62 ppm, and a doublet at 7.82 ppm. The other resonance
signals were assigned to p-cresyl sulphate. Moreover, Figure 1B
Figure 1. Comparison of deproteinization methods. 500 MHz 1H-NMR spectrum of plasma from CKD patient following (A) ultrafiltration, (B)
acetonitrile precipitation or (C) PCA extraction.
doi:10.1371/journal.pone.0071199.g001
Figure 2. 500 MHz 1H-NMR spectra: region d 7.00–7.80 and 3.00–2.00. (A) Authentic reference solution of p-cresyl sulphate with chemical
structure and assignments. (B) Plasma (acetonitrile precipitation) from CKD patient. The spectrum shows resonances of p-cresyl sulphate. These
resonances were not observed in plasma from controls.
doi:10.1371/journal.pone.0071199.g002
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also shows that the citric acid peak observed following ultrafiltra-
tion is lost by acetonitrile deproteinization. Furthermore, PCA
extraction resulted in an overall decreased sensitivity, a poor
signal-to-noise ratio and shifts in peak position (Figure 1C), making
this method unsuitable for metabolite identification and quanti-
fication. To our knowledge, this is the first report to demonstrate
the presence of p-cresyl sulphate in plasma using 1H-NMR
spectroscopy. Therefore, we aimed to verify the identity of the
detected metabolite using a reference standard. 1H-NMR of the
authentic compound p-cresyl sulphate in H2O at pH 2.5
(Figure 2A) showed a singlet at 2.33 ppm (CH3 group) and a
doublet at both 7.19 ppm and 7.27 ppm (aromatic ring protons).
A similar resonance profile was observed in acetonitrile-treated
plasma from a CKD patient (Figure 2B), indicating that p-cresyl
sulphate is indeed retained in patients with kidney failure. The
absence of both hippuric acid and p-cresyl sulphate in plasma
following ultrafiltration is most likely due to the strong protein
binding of these solutes. Thus, ultrafiltration and acetonitrile
extraction are complementary deproteinization strategies and both
methods are required to obtain a clear overview of the metabolic
status of non-dialysis CKD patients.
Accumulation of Uremic Toxins in Patients with CKD
Stage 3–4
1H-NMR spectroscopy revealed that a plethora of uremic
compounds are elevated in CKD patients as compared with
healthy controls (Figure 3). Resonance assignments were based on
previously recorded spectra and a total of 14 solutes could be
assigned. As expected, creatinine was elevated in all patients.
Moreover, the well-known toxins 3-methylhistidine, hippuric acid,
Figure 3. Accumulation of uremic solutes. 500 MHz 1H-NMR spectrum of plasma (ultrafiltrate) from (A) a healthy control and (B) a CKD patient.
Insets show 5 regions of interest in greater detail. Metabolite abnormalities: Creatinine (1 and 2), 1-methylhistidine (3), 3-methylhistidine (4), myo-
Inositol (5), trimethylamine N-oxide (6), dimethyl sulphone (7), N,N-dimethylglycine (8) and 2-hydroxyisobutyric acid (9).
doi:10.1371/journal.pone.0071199.g003
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p-cresyl sulphate, N,N-dimethylglycine, betaine and myo-inositol
were detected in all patients. In all ten patient samples we also
detected the hitherto unknown toxins DMSO2 and 2-HIBA. 1-
methylhistidine was detected in nine patients, trigonelline and
trimethylamine N-oxide were found in six patients and pseudo-
uridine was found in five patients; whereas, dimethylamine was
only detected in one individual. Resonance assignments and
concentrations of uremic toxins measured by 1H-NMR are
summarized in Table 2 and chemical structures can be found in
Figure S1.
Comparison with Normal Concentrations
To evaluate the relative solute retention in stage 3–4 CKD
patients, the ratio of the mean of all uremic concentrations (M)
determined were calculated to the normal concentration (N)
reported in literature (M/N), as described previously [5]. The
solute solely retained in one patient (i.e. dimethylamine), trigonel-
line (due to lack of reference value) and creatinine were excluded
from this analysis. The M/N ratio ranged from 2.3 for trimeth-
ylamine N-oxide to 44.7 for hippuric acid (Figure 4). In the case of
five metabolites, the uremic concentration was more than 10 times
higher than normal. A moderate degree of retention was observed
for four solutes for which the M/N ratio ranged between 4 and 10.
Correlation between eGFR and Retention of DMSO2 and
2-HIBA
Next, we investigated whether the plasma concentration of
DMSO2 and 2-HIBA in non-dialysis CKD patients correlated
with a decline in kidney function as represented by the eGFR. As
shown in both Figure 5 and Figure S2, there is no association
between the parameters studied as concluded from a Spearman
correlation analysis (r,0.2 for both solutes).
Influence of Uremic Solutes on ciPTEC Phenotype
The impact of the novel uremic retention solutes on proximal
tubular epithelium was investigated using a unique human
proximal tubule cell line, demonstrated to be a valid model to
study nephrotoxicity and renal cell metabolism [17–19]. Exposure
of ciPTEC to the Cmax of DMSO2 or 2-HIBA, determined in this
study (Table 2), resulted in an increase in vimentin expression by
12% and 30%, respectively (Figure. 6A). Moreover, at the highest
concentration tested (10x Cmax,) these toxins increased vimentin
expression by 26% and 55%, respectively. In comparison, both 1-
methylhistidine and 3-methylhistidine did not affect vimentin
expression; whereas the positive control (indoxyl sulphate)
increased vimentin expression by 55% (Figure 6B). Flow cytometry
revealed that exposure to the highest concentration of both solutes
did not affect cell morphology nor the percentage of living cells as
compared to untreated cells (Figure 6C). Furthermore, when
ciPTEC were exposed to the Cmax, UGT activity was reduced by
8% and 13%, respectively. And we observed a clear correlation
between vimentin expression and UGT activity with a calculated
Pearson r of20.63 (p,0.05; Figure 6D). In addition, DMSO2 and
2-HIBA did not impede mitochondrial succinate dehydrogenase
activity as demonstrated with the MTT assay (Figure 6E). Taken
together, our findings suggest that both solutes induce a loss of
epithelial characteristics and reduce renal glucuronide formation,
indicating changes in cell metabolism without affecting cell
viability.
Discussion
Accumulation of uremic toxins due to inadequate renal
clearance is a hallmark of CKD. Uremic retention solutes are
associated with disease progression and the myriad of pathologies
observed in dialysis patients. In this study, 1H-NMR spectroscopy
was successfully used to indentify multiple uremic toxins in the
plasma of stage 3–4 CKD patients.
Our results revealed that ultrafiltration and acetonitrile extrac-
tion are complementary deproteinization techniques and both are
required as sample preparation methods for the proper detection
Figure 4. Relative retention of uremic solutes in stage 3–4 CKD
patients. The M/N index is the ratio of the mean uremic concentration
(M) found in the present study to the normal concentration (N)
measured in healthy controls reported in literature.
doi:10.1371/journal.pone.0071199.g004
Figure 5. Correlation between plasma solute levels and eGFR. Dots represent the natural logarithm (LN) of individual concentrations of
DMSO2 and 2-HIBA and the lines the best fit linear regression line with the 95% confidence interval.
doi:10.1371/journal.pone.0071199.g005
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Figure 6. Impact of DMSO2 and 2-HIBA on ciPTEC. Cells were exposed for 48 h to ciPTEC medium (gray bar), DMSO2 or 2-HIBA (concentration
range: K Cmax–10x Cmax). (A) Following treatment, cells were harvested and stained with mouse-a-human Vimentin-PE. Quantification of staining
was done with a BD FACSCalibur flow cytometer using channel FL-2, and analyzed with FlowJo software, gating on live cells. Statistical analysis was
performed via a One-way ANOVA followed by the Dunnett’s Multiple Comparison Test for each toxin. Results are presented as mean 6 SEM of three
independent experiments performed in duplicate or triplicate. * indicates p,0.05 compared with control. (B) Vimentin expression following exposure
to 1 mM 1-methylhistidine (1-MH), 3-methylhistidine (3-MH; both negative control) or indoxyl sulphate (IS; positive control) for 48 h. Results are
presented as mean6 SEM of three independent experiments performed in duplicate or triplicate. * indicates p,0.05 compared with control. (C) Cells
were exposed for 48 h to ciPTEC medium, DMSO2 or 2-HIBA (both 10x Cmax). Representative density plots with percentage of gated (i.e. living) cells of
three independent experiments, performed in duplicate or triplicate (D) Following treatment, ciPTEC were incubated for 3 h with 10 mM 7-OHC.
Afterwards, an aliquot of culture medium was collected and injected into the HPLC-system. Standards of 7-OHCG were also analyzed in order to
quantify the amount of glucuronide found in the samples. Acquired HPLC data were processed with PC1000 software (Spectrasystem). Pearson
correlation analysis revealed a significant association between the expression of vimentin and glucuronidation (r =20.63; p,0.05). (E) The MTT assay
was used to study the impact of DMSO2 and 2-HIBA on mitochondrial metabolism. Cells were exposed for 48 h to both solutes as described above.
Afterwards, cells were incubated for 4 h with MTT-solution at 37uC. Subsequently, produced formazan crystals were dissolved in DMSO and extinction
was measured at 570 nm. Results are presented as mean 6 SEM of three independent experiments performed minimally in triplicate.
doi:10.1371/journal.pone.0071199.g006
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of uremic retention solutes using 1H-NMR spectroscopy. In the
study of Tiziani et al., it was demonstrated that ultrafiltration was
the best deproteinization strategy to remove proteins from serum
samples resulting in a high metabolite retainment and reproduc-
ibility [20]. Furthermore, they reported that following acetonitrile
extraction most of the metabolites were maintained, although with
a reduced signal intensity compared to ultrafiltration [20]. In
contrast, Daykin et al., demonstrated that deproteinization using
acetonitrile at physiological pH resulted in an increased detection
of low-molecular-weight metabolites and a improved signal-to-
noise ratio [11]. These studies corroborate our notion that
multiple deproteinization strategies are needed when investigating
the metabolome.
Here, we report for the first time that DMSO2 and 2-HIBA are
retained in CKD patients. Moreover, both solutes were demon-
strated to negatively influence renal cell physiology using ciPTEC.
Already in 1966, Williams et al. reported the presence of DMSO2
in urine [21]. Yet, it took several decades to establish that DMSO2
is a common metabolite present in blood and cerebrospinal fluid
[22,23]. DMSO2 can originate from dietary sources such as, milk
and port wine [23–25]. Moreover, it can be formed during
bacterial metabolism of methanethiol in the gut or endogenous
human methanethiol metabolism [23,26]. Recently, it has been
described that DMSO2 attenuated both constitutive as well as IL-
1b-induced IL-6 and IL-8 production in human chondrocyte cell
line, possibly by inhibiting the ERK1/2 signaling pathway [27].
Older studies indicated that DMSO2 inhibited oxidant production
in activated neutrophils and diminished the proliferation of
vascular smooth muscle cells and endothelial cells [28,29].
Regarding 2-HIBA, two recent studies reported that this
compound is constitutively present in human urine and serum
[30,31]. Moreover, 2-HIBA is the major urinary metabolite in
humans following exposure to the gasoline additives methyl-
tert.butyl ether and ethyl-tert.butyl ether [32,33]. Elevated plasma
concentrations of 2-HIBA were observed in patients with type 2
diabetes mellitus, possibly due to disturbances in fatty acid
metabolism [34]. Moreover, a recent genome-wide association
study revealed a significant negative association with urinary 2-
HIBA levels and SNP rs830124, an intronic SNP of the WDR66
gene on chromosome 12, which is closely associated with mean
platelet volume [35,36]. At present, little is known regarding the
biological activity of DMSO2 and 2-HIBA. Our results provide the
first proof that these metabolites induce a loss of defined renal
epithelial features and are possibly involved in the progression of
CKD. However, more research is necessary to definitely label
these solutes as uremic toxins.
It is known that uremic toxin levels rise in concordance with
CKD severity [2]. Therefore, it is suggested that eGFR, as a
marker of kidney function, should reflect retention state and the
levels of uremic solutes in CKD patients. In this study, we did not
observe any correlation between eGFR and plasma concentration
of DMSO2 or 2-HIBA, which suggests that eGFR is a poor marker
for the accumulation of these solutes. These findings are in
agreement with previous studies demonstrating that eGFR is an
unsuitable tool to predict levels of uremic toxins from different
classes (e.g. middle weight and protein-bound) in CKD patients
[37,38]. Furthermore, these results suggest that the renal clearance
of both metabolites is mainly dependent on active tubular
transport, possibly due to binding of the compounds to plasma
proteins. Yet, more research is needed to fully elucidate the
chemical properties, including protein-binding, of DMSO2 and 2-
HIBA.
Next to DMSO2 and 2-HIBA, the present study showed that 1-
methylhistidine, 3-methylhistidine, hippuric acid, p-cresyl sul-
phate, N,N-dimethylglycine, pseudouridine, betaine, myo-inositol
and trimethylamine N-oxide were elevated in stage 3–4 CKD
patients. Previously, Choi et al., used 1H-NMR spectroscopy to
study the metabolic status of dialysis patients [39]. They reported
that a multitude of uremic toxins were retained including myo-
inositol and 3-methylhistidine, similar to our findings in non-
dialysis CKD patients. In addition, Rhee et al. studied the
metabolomic profile of 44 hemodialysis patients using three
different LC-MS methods [4]. In total, 40 metabolites were
elevated at baseline in patients, compared to healthy controls. In
concordance with our results, they demonstrated retention of
hippuric acid, trimethylamine N-oxide and dimethylglycine. Both
studies did not report the retention of 1-methylhistidine, pseudo-
uridine and betaine. However, accumulation of 1-methylhistidine
in patients treated with hemodialysis has been demonstrated by
HPLC previously [40]. And Niwa et al., reported that pseudouri-
dine levels were increased in both CRF and dialysis patients
compared with controls [41]. Taken together, there is a clear
overlap in the solutes retained in both the early stages of CKD and
patients with end-stage renal disease.
Previously, using HPLC and LC-MS/MS, our group demon-
strated that indole-3-acetic acid, indoxyl sulfate and kynurenic
acid accumulated in CRF patients with mean concentrations of
4.4 mM, 67 mM and 0.6 mM, respectively [2]. These compounds
were not identified during the present study due to the limited
sensitivity of proton NMR spectroscopy. Other widely deployed
techniques, such as HPLC and LC-MS/MS, have a higher
sensitivity with detection limits in the nano- or even picomolar
range although the sensitivity highly varies depending on the
compound of interest. The present study was an initial proof-of-
concept study to determine whether 1H-NMR spectroscopy could
be used as a tool to expand our knowledge about uremic retention
solutes and if this technique can be utilized in the search for CKD
biomarkers. As such, a small number of CKD patients was
included, which limited our power to identify uremic retention
solutes for which levels greatly differ among individual patients.
Still, the current study is the first to provide an overview of the
metabolome of non-dialysis CKD patients by means of NMR
spectroscopy. One has to take into account that, due to the reasons
stated above, not all of the potential toxic solutes retained in stage
3–4 CKD patients are identified. Further studies with additional
subjects and analytical techniques should provide a more complete
overview of metabolites retained in CKD patients.
In conclusion, a hallmark of renal failure is the retention of a
plethora of metabolites, belonging to multiple physico-chemical
classes, with potential deleterious effects on total body homeostasis.
In this study, we have demonstrated that both ultrafiltration and
acetonitrile extraction are required as deproteinization methods to
elucidate the metabolomic profile of stage 3–4 CKD patients by
means of 1H-NMR spectroscopy. Moreover, using this technique,
we have successfully identified a total of 14 metabolites, including
2 novel uremic solutes, that possibly contribute to the co-morbidity
and mortality in CKD patients. These results might aid in
revealing new biomarkers for CKD and possibly contribute to a
better understanding of the progressive character of renal disease.
Supporting Information
Figure S1 Chemical structures of uremic solutes de-
tected in stage 3–4 CKD patients. Structures obtained from
the Human Metabolome Database (www.hmdb.ca) [42].
(TIF)
Figure S2 Correlation between plasma solute levels
(mM) and eGFR. Dots represent the individual concentrations
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of DMSO2 and 2-HIBA and the lines the best fit linear regression
line with the 95% confidence interval. Nonparametric Spearman
correlation analysis revealed no significant correlation between the
two studied parameters for both DMSO2 (r =20.17; p= 0.6) and
2-HIBA (r =20.03; p = 0.9).
(TIF)
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